Sydney, Australia-based medicinal cannabis manufacturer, THC Global Group announced Tuesday that it obtained another manufacturing license for its subsidiary THC Pharma Pty Ltd from the Australian Office of Drug Control.
The company said its Southport manufacturing site is the largest biopharmaceutical extraction facility in the southern hemisphere.
"We are ready to commence GMP API production of medicinal cannabis at globally significant volumes and at very competitive prices," THC Global CEO Ken Charteris said in a statement.
Need more cannabis news? Check out all of our coverage here.
We expect to be supplying Australian patients with Australian-produced medicinal cannabis by early 2020, as well as responding to the rapidly expanding global demand for pharma-grade GMP API isolates and formulated medicines."
When it comes to the international market, the company’s focus is on Asia, where it aims to export its products for use in foreign studies and clinical trials.
Related Links:
Green Growth Brands To Purchase Moxie For $310M, Create '360 Degree' Cannabis Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.